Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain(MedStar Washington Hospital Center), Sung‐Bae Kim(University of Ulsan), Javier Cortés(Vall d'Hebron Institute of Oncology), Jungsil Ro(National Cancer Center), Semiglazov Vf(Institute of Oncology NN Petrov), Mario Campone(Institut de Cancérologie de l'Ouest), Eva Ciruelos(Research Institute Hospital 12 de Octubre), Jean-Marc Ferrero(Centre Antoine Lacassagne), Andreas Schneeweiß, Adam Knott(Roche (Switzerland)), Emma Clark(Roche (Switzerland)), Graham Ross(Roche (Switzerland)), Mark Benyunes, José Baselga(Memorial Hospital)
Cited by 998Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis